Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways (Q39732580)

14 September 2017

title

Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways (English)

1 reference

14 September 2017

T Kobayashi

1 reference

14 September 2017

J Kuroda

1 reference

14 September 2017

E Ashihara

1 reference

14 September 2017

S Oomizu

1 reference

14 September 2017

Y Terui

1 reference

14 September 2017

A Taniyama

1 reference

14 September 2017

S Adachi

1 reference

14 September 2017

T Takagi

1 reference

14 September 2017

M Yamamoto

1 reference

14 September 2017

N Sasaki

1 reference

14 September 2017

S Horiike

1 reference

14 September 2017

K Hatake

1 reference

14 September 2017

A Yamauchi

1 reference

14 September 2017

M Hirashima

1 reference

14 September 2017

M Taniwaki

1 reference

14 September 2017

publication date

4 March 2010

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

page(s)

843-850

1 reference

Galectins: a family of animal beta-galactoside-binding lectins

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Binding and cross-linking properties of galectins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Galectins: a new family of regulators of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Galectin-9 induces maturation of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Characterization of galectin-9-induced death of Jurkat T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

A modified version of galectin-9 suppresses cell growth and induces apoptosis of human T-cell leukemia virus type I-infected T-cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

H2AX is a target of the JNK signaling pathway that is required for apoptotic DNA fragmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Serum starvation induces H2AX phosphorylation to regulate apoptosis via p38 MAPK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Overview of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

7 January 2021

Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

7 January 2021

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

7 January 2021

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

7 January 2021

ER stress induces caspase-8 activation, stimulating cytochrome c release and caspase-9 activation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.25

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.25

1 reference

14 September 2017

1 reference